Document Detail

Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors.
MedLine Citation:
PMID:  16765146     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Our objective was to investigate the association between the -344C/T or A6547G polymorphism of the aldosterone synthase gene and the blood pressure response to angiotensin-converting enzyme inhibitors in a hypertensive cohort. METHODS: After a 2-week single-blind placebo run-in period, either benazepril or imidapril was administered for 6 weeks to 509 patients with mild to moderate essential hypertension. Polymerase chain reaction combined with restriction enzyme digestion was used to detect the 2 polymorphisms. The achieved changes in systolic and diastolic blood pressure were analyzed for their association with genotypes at the aldosterone synthase gene loci. RESULTS: Regarding the -344C/T polymorphism, we observed the CC genotype in 53 patients (10.4%), the CT genotype in 204 (40.1%), and the TT genotype in 252 (49.5%). After 6 weeks of treatment, the reductions in diastolic blood pressure were significantly greater in patients carrying the TT or CT genotype compared with those carrying the CC genotype (9.1+/-7.0 mm Hg or 8.9+/-7.0 mm Hg versus 5.1+/-7.3 mm Hg, respectively; P=.001, ANOVA). Regarding the A6547G polymorphism, we observed the AA genotype in 19 patients (3.7%), the AG genotype in 184 (36.2%), and the GG genotype in 306 (60.1%). There were no significant differences in the blood pressure reductions after treatment among the 3 genotype groups, and there was no interaction between it and the -344C/T polymorphism. Stepwise multiple regression analysis showed that the significant predictors of diastolic blood pressure reduction at 6 weeks were baseline diastolic blood pressure (P<.001), -344C/T genotype (P=.007), and sex (P=.033). CONCLUSIONS: The -344C/T variant, but not the A6547G variant, of the aldosterone synthase gene may be a determinant of the blood pressure response to angiotensin-converting enzyme inhibitors in hypertensive patients.
Hui-Min Yu; Shu-Guang Lin; Guo-Zhang Liu; Yu-Qing Zhang; Wen-Jun Ma; Chun-Yu Deng
Related Documents :
16216916 - Peroxisome proliferator-activated receptor gamma and its coactivator-1 alpha may be ass...
6572186 - A paradigm for identification of primary genetic causes of hypertension in rats.
22675496 - Cxcr3 antagonism of sdf-1(5-67) restores trabecular function and prevents retinal neuro...
6601536 - A note on estimating selection pressures on insecticide-resistance genes.
19894656 - Definition of hypertension: the impact of number of visits for blood pressure measurement.
9386166 - Prospective prognostic assessment of blood pressure response during exercise in patient...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  79     ISSN:  0009-9236     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-06-12     Completed Date:  2006-07-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  581-9     Citation Subset:  AIM; IM    
Department of Cardiology, Guangdong Provincial People's Hospital and Guangdong Cardiovascular Institute, Guangzhou, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Aldosterone Synthase / genetics*
Angiotensin-Converting Enzyme Inhibitors / administration & dosage,  blood,  pharmacokinetics,  pharmacology*
Asian Continental Ancestry Group / genetics
Benzazepines / administration & dosage,  blood,  pharmacokinetics,  pharmacology
Blood Pressure / drug effects*
Hypertension / drug therapy,  genetics*,  pathology
Imidazolidines / administration & dosage,  blood,  pharmacokinetics,  pharmacology
Middle Aged
Polymorphism, Genetic
Severity of Illness Index
Single-Blind Method
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Benzazepines; 0/Imidazolidines; 86541-75-5/benazepril; 89396-94-1/imidapril; EC Synthase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.
Next Document:  Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy su...